Investors
Press Releases
Press releases issued by Palatin are accessible below. These press releases contain additional information about our business, clinical trial developments, research and development activities, financial achievements, and strategic partnerships.
Found 329 Results
Palatin Issued Patent on Vyleesi® (Bremelanotide Injection) For Hypoactive Sexual Desire Disorder in Patients With Controlled Hypertension
February 28, 2023
Palatin Reports Second Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
February 15, 2023
Palatin to Report Second Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on February 15, 2023
February 10, 2023
Palatin Initiates Enrollment in the Phase 2 Bremelanotide BREAKOUT Study in Patients with Diabetic Kidney Disease
January 19, 2023
Palatin Receives $4.7 Million of Non-Dilutive Funding
January 18, 2023
Frontiers in Immunology Publishes Pre-Clinical Study of Palatin’s PL8177 Demonstrating Therapeutic Effects in Inflammatory Conditions
January 10, 2023
Palatin Announces Preliminary Second Quarter Fiscal 2023 Vyleesi® Product Sales Results
January 5, 2023
Palatin Reports First Quarter Fiscal Year 2023 Financial Results and Provides Corporate Update
November 14, 2022
Palatin to Report First Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on November 14, 2022
November 9, 2022
Palatin Announces $10 Million Registered Direct Offering
October 31, 2022
Page 8 of 33